Nkarta, Inc. (NKTX)
Automate Your Wheel Strategy on NKTX
With Tiblio's Option Bot, you can configure your own wheel strategy including NKTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NKTX
- Rev/Share 0.0
- Book/Share 5.1248
- PB 0.3551
- Debt/Equity 0.2083
- CurrentRatio 14.4781
- ROIC -0.2826
- MktCap 129142832.0
- FreeCF/Share -1.428
- PFCF -1.2235
- PE -1.2092
- Debt/Assets 0.1677
- DivYield 0
- ROE -0.2663
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 5
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NKTX | William Blair | Outperform | Market Perform | -- | -- | May 15, 2025 |
| Initiation | NKTX | Rodman & Renshaw | -- | Buy | -- | $14 | Oct. 9, 2024 |
News
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pursue other opportunities in the oncology space.
Read More
Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Nkarta (NKTX) Upgraded to Buy: Here's Why
Published: April 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Nkarta: Grinding Lower, Trying To Find Support
Published: March 31, 2025 by: Seeking Alpha
Sentiment: Positive
Nkarta, Inc. has provided significant pipeline updates, showcasing promising advancements in their innovative cell therapy treatments. A financial overview highlights a robust balance sheet, with sufficient cash reserves to support ongoing research and development activities. Strengths include cutting-edge technology and strategic partnerships, while risks involve clinical trial uncertainties and regulatory hurdles.
Read More
Nkarta (NKTX) Loses -33.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Negative
The heavy selling pressure might have exhausted for Nkarta (NKTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
Nkarta to Participate in March Investor Conferences
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences:
Read More
About Nkarta, Inc. (NKTX)
- IPO Date 2020-07-10
- Website https://www.nkartatx.com
- Industry Biotechnology
- CEO Mr. Paul J. Hastings
- Employees 157